Back

Pfizer’s LITFULO improves repigmentation in nonsegmental vitiligo

Verifying
  • Pfizer’s LITFULO improved repigmentation in patients with nonsegmental vitiligo.
  • Facial and total-body repigmentation both improved, according to the report.
  • The report identifies the patient population as having nonsegmental vitiligo.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.